# sinocelltech

**Canonical:** https://apis.io/providers/sinocelltech/  
**Website:** https://sinocelltech.com  
**APIs profiled:** 0

Sinocelltech (Beijing Sino Cell Biotechnology Group Co., Ltd.; Shanghai Stock Exchange STAR Market code 688520) is a biopharmaceutical research and development company founded in 2002 by Dr. Xie Liangzhi. It develops and commercializes recombinant protein and monoclonal antibody therapeutics across oncology, autoimmune disease, and infectious disease, together with preventive vaccines including a recombinant 14-valent HPV vaccine and COVID-19 vaccines. The company has multiple marketed products in China and a pipeline of clinical-stage candidates. It publishes no public developer platform, API, or technical documentation surface.

## Kin Score — 5.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 5.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Sinocelltech Domain Security** — TLSv1.2 · DMARC

## Tags

Company, Biotechnology, Biopharmaceutical, Pharmaceuticals, Vaccines, Monoclonal Antibodies, Oncology, China

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/sinocelltech/). Scores are computed from the provider's own public artifacts under a published rubric.